Researchers at Politecnico di Torino have developed new energy storage technology that could help tackle two major global challenges: reducing industrial carbon emissions and boosting renewable energy efficiency.
With eyewitness awareness of how six million Jewish people lost their lives, aging Holocaust survivors have carried an impossible burden - now, researchers are attempting to document the lifelong impact of trauma.
Matthew Margetts, Director of Sales and Marketing at Smarter Technologies, discusses how ports and marinas are strengthening their supply chain and digitilising their shipping processes with IoT solutions.
AstraZeneca CEO Pascal Soriot spoke to Antonello Guerrera about the ongoing vaccine feud - with the Commission receiving 60% less than expected, raising tense questions about why.
Prime Minister Boris Johnson announced that he had done "everything possible" to prevent 100,000 COVID deaths, as the UK witnesses 50,099 fatalities in the space of 79 days.
Miles Tappin, VP of EMEA at ThreatConnect, discusses why it is essential for CISOs to explain to their fellow C-suite executives and board of directors how at risk their organisations actually are from cyber events.
The BlueInvest fund today allocated the first of an available €75 million to two projects working against food insecurity - announcing the names at a BlueInvest Day event.
New vaccine data from Israel suggests that the double-dose of Pfizer is performing at the expected rate of 95% efficiency - with the possibility that it is performing even better than that being further investigated.
Researchers have found that neurofeedback, or 'brain training', may be an effective treatment for individuals with post-traumatic stress disorder (PTSD).
In response to the AstraZeneca feud, EU officials are creating a "transparency mechanism" for vaccine exports - which would indirectly hold companies accountable for fulfilling their agreed contracts.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
